Skip to main content

Advertisement

SpringerLink
Log in

Mechanisms of thrombocytopenia induced by interferon therapy for chronic hepatitis B

  • Liver, Pancreas, and Biliary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

To clarify the mechanisms of thrombocytopenia observed in patients with chronic hepatitis B treated with interferon. We studied six patients with chronic active hepatitis B who received intramuscular injections of natural interferon-alpha (3 or 5 million IU/day) for 4 weeks. Peripheral blood platelet counts, bone marrow findings, and platelet kinetics, determined using111In-labeled platelets, were analyzed. Platelets decreased significantly 1 week after the beginning of treatment and remained decreased until the completion of treatment. The number of nucleated cells and megakaryocytes in bone marrow decreased in three of five patients studied during treatment. The kinetic study showed platelet survival time to be 8.1±1.3 days (range, 5.8–10.0). One day after platelet injection, platelets accumulated predominantly in the splenic area in all patients, whereas hepatic accumulation was predominant 7 days after injection in three of the six patients. Thrombocytopenia during interferon treatment arises from the inhibition of stem cell proliferation and differentiation in the bone marrow and from the capture of platelets by the liver.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Greenberg BH, Pollard BR, Lutwick IL, et al. Effect of human leukocyte interferon on hepatits B virus infection in patients with chronic active hepatitis. New Engl J Med 1976;295:511–522.

    Google Scholar 

  2. Hoofnagle JH, Mulen KD, Jones DB, et al. Treatment of chronic non-A, non B hepatitis with recombinant human alpha interferon. New Engl J Med 1986;315:1575–1578.

    PubMed  CAS  Google Scholar 

  3. Davis GL, Balart LA, Shiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alpha. N Engl J Med 1989;321:1501–1506.

    PubMed  CAS  Google Scholar 

  4. Hoshino U, Suou T, Kawasaki H. Evaluation of side effects of interferon therapy by questionnaire in chronic hepatitis C. Acta Hepatol Jap 1995;36:506–510.

    Google Scholar 

  5. Ernstoff MS, Kirkwood JM. Changes in the bone marrow of cancer patients treated with recombinant interferon alpha-2. Am J Med 1984;76:593–596.

    Article  PubMed  CAS  Google Scholar 

  6. van't Hull E, Schellekens H, Löenberg B, et al. Influence of interferon preparations on the proliferative capacity of human and mouse bone marrow cells in vitro. Cancer Res 1978;38:911–914.

    Google Scholar 

  7. Hansson M, Beran M, Andersson B, et al. Inhibition of in vitro granulopoiesis by autologous allogeneic human NK cells. J Immunol 1982;129:126–132.

    PubMed  CAS  Google Scholar 

  8. Heumann HA, Fauser AA. Effect of interferon on pluripotent hemopoietic progenitors (CFU-GEMM) derived from human bone marrow. Exp Hematol 1982;10:587–590.

    Google Scholar 

  9. Mazur EM, Richtsmeier WJ, South K. Alpha-interferon: Differential suppression of colony growth from human erythroid, myeloid, and megakaryocytic hematopoietic progenitor cells. J Int Res 1986;6:199–206.

    CAS  Google Scholar 

  10. Talpaz M, Spitzer G, Hittelman W, et al. Changes in granulocytemonocyte colony-forming cells among leulocyte-interferontreated chronic myelogenous leukemia patients. Exp Hematol 1986;14:668–671.

    PubMed  CAS  Google Scholar 

  11. Ganser A, Carlo-Stella C, Greher J, et al. Effect of recombinant interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells. Blood 1987;70:1173–1179.

    PubMed  CAS  Google Scholar 

  12. Abdi EA, Brien W, Venner PM. Auto-immune thrombocytopenia related to interferon therapy. Scand J Haematol 1986;36:515–519.

    PubMed  CAS  Google Scholar 

  13. McLaughlin P, Talpaz M, Quesada JR, et al. Immune thrombocytopenia following α-interferon therapy in patients with cancer. JAMA 1985;254:1353–1354.

    Article  PubMed  CAS  Google Scholar 

  14. Terada H. Structure of platelets and megacaryocytes. Atlas of clinical examination. Blood 1978;2:78–86.

    Google Scholar 

  15. Dewanjee MK, Rao SA, Didisheim P. Indium-111 tropolone, a new high affinity platelet label: Preparation and evaluation of labeling parameters. J Nucl Med 1981;22:981–987.

    PubMed  CAS  Google Scholar 

  16. ICSH panel on diagnostic application of radioisotopes in hematology: Recommended methods for radioisotope platelet survival studies. Blood 1977;50:1137–1144.

    Google Scholar 

  17. Hino K. Clinical pharmacology of interferon α and β. Biomed Therapeut 1993;27:1185–1192.

    Google Scholar 

  18. Thakur ML, Welch MJ, Joist G, et al. Indium-111 labeled platelets. Studies on preparation and evaluation of in vitro and in vivo function. Thromb Res 1976;9:345–357.

    Article  PubMed  CAS  Google Scholar 

  19. Klonizakis I, Peters AM, Fitzpatrick ML, et al. Radionuclide distribution following injection of,111Indium-labelled platelets. Br J Haematol 1980;46:595–602.

    Article  PubMed  CAS  Google Scholar 

  20. Toghill PJ, Green S. Platelet dynamics in chronic liver disease using the111Indium oxine label. Gut 1983;24:49–52.

    Article  PubMed  CAS  Google Scholar 

  21. Schmidt KG, Rasmussen JW, Bekker C, et al. Kinetics and in vivo distribution of111In-labeled autologous platelets in chronic hepatic disease: Mechanisms of thrombocytopenia. Scand J Haematol 1985;34:39–46.

    PubMed  CAS  Google Scholar 

  22. Schmidt KG, Rasmussen JW. Kinetics and distribution in vivo of111In-labelled autologous platelets in idiopathic thrombocytopenic purpura. Scand J Haematol 1985;34:47–56.

    PubMed  CAS  Google Scholar 

  23. Peters AM, Saverymuttu SH, Bell RN, Lavender JP. The kinetics of short-lived indium-111 radiolabelled platelets. Scand J Haematol 1985;34:137–145.

    PubMed  CAS  Google Scholar 

  24. Peters AM, Saverymuttu SH, Malik F, et al. Intrahepatic kinetics of indium-111-labelled platelets. Thromb Haemost 1985;54:595–598.

    PubMed  CAS  Google Scholar 

  25. Louwes H, Beekhuis H, Goedemans WTH, et al.111Intropolonate labelled platelets; studies in normals and in patients with thrombocytopenia. Eur J Nucl Med 1987;13:47–51.

    Article  PubMed  CAS  Google Scholar 

  26. Aoki Y, Hirai K, Tanikawa K. Mechanism of thrombocytopenia in liver cirrhosis: Kinetics of indium-111 tropolone labelled platelets. Eur J Nucl Med 1993;20:123–129.

    Article  PubMed  CAS  Google Scholar 

  27. Heyns AP, Löter MG, Badenhorst PN, et al. Kinetics and in vivo redistribution of111Indium-labelled human platelets after intravenous protamine sulfate. Thromb Haemost 1980;44:65–68.

    PubMed  CAS  Google Scholar 

  28. Cornacoff JB, Hebert LA, Smead WL, et al. Primate erythrocyteimmune complex-clearing mechanism. J Clin Invest 1983;71:236–247.

    Article  PubMed  CAS  Google Scholar 

  29. Karas SP, Rosse WF, Kurlander RJ. Characterization of IgG-Fc receptor on human platelets. Blood 1982;60:1277.

    PubMed  CAS  Google Scholar 

  30. Pace JL, Russell SW, LeBlanc PA, et al. Comparative effects of various classes of mouse interferons on macrophage activation for tumor cell killing. J Immunol 1985;134:977–981.

    PubMed  CAS  Google Scholar 

  31. Prieto J, Yuste JR, Beloqui Q, et al. Anticardiolipin antibodies in chronic hepatitis C: Implication of hepatitis C virus as the cause of the antiphospholipid syndrome. Hepatology 1996;23: 199–204.

    Article  PubMed  CAS  Google Scholar 

  32. Herbert JM, Savi P, Laplace MC, et al. IL-4 and IL-13 exhibit comparable abilities to reduce pyrogen-induced expression of procoagulant activity in endothelial cells monocytes. FEBS Lett 1993;328:268–270.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Second Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, 830, Kurume, Fukuoka, Japan

    Michio Sata, Yoichi Yano, Yasutsugu Yoshiyama, Tatsuya Ide, Ryukichi Kumashiro, Hiroshi Suzuki & Kyuichi Tanikawa

Authors
  1. Michio Sata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoichi Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasutsugu Yoshiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tatsuya Ide
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ryukichi Kumashiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroshi Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kyuichi Tanikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sata, M., Yano, Y., Yoshiyama, Y. et al. Mechanisms of thrombocytopenia induced by interferon therapy for chronic hepatitis B. J Gastroenterol 32, 206–210 (1997). https://doi.org/10.1007/BF02936369

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02936369

Key words

Search

Navigation